Alejandro Escobedo-Calvario

Alejandro Escobedo-Calvario

Auto-generated profile, based on publicly available information

Alejandro Escobedo-Calvario

Posgrado en Biología Experimental, DCBS, Universidad Autónoma Metrolitana-Iztapalapa, Mexico City 09340, Mexico 2Área de Medicina Experimental y Traslacional, Departamento de Ciencias de la Salud, Universidad Autónoma Metropolitana-Iztapalapa, Mexico City 09340, Mexico

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2022
Verified
Journal Article
Open access
PDF file
AEAlejandro Escobedo-Calvario
Alejandro Escobedo-Calvario
LCLisette Chavez-Rodríguez
Lisette Chavez-Rodríguez
ASArturo Simoni
Arturo Simoni
VSVerónica Souza-Arroyo
Verónica Souza-Arroyo
RMRoxana U. Miranda-Labra
Roxana U. Miranda-Labra
MGMaría Concepción Gutierrez-Ruiz
María Concepción Gutierrez-Ruiz
Hepatocellular carcinoma (HCC) is considered one of the most aggressive tumors worldwide. The consumption of lipid-enriched diets, mainly high cholesterol, induces oxidative stress and chronic inflammation, leading to HCC progression. Moreover, fatty acids and cholesterol could display differential responses on immune cells inside the tumor immune microenvironment (TIME). Tumor-associated macrophages (TAMs) represent one of the most critical leukocytes in the tumor microenvironment (TME) displaying pro-tumoral responses and one of the mainly cholesterol donors to cancer cells. Immunotherapy or cholesterol regulators, alone or combined, would represent an effective strategy for HCC treatment. Nonetheless, steatotic etiology from non-alcoholic fatty liver disease (NAFLD)-HCC tumors has been unexpectedly resulting in highly aggressive behavior.

11 August 2022
Verified
Journal Article
Open access
PDF file
JLJocelyn López-Ramirez
Jocelyn López-Ramirez
RLRoberto Lazzarini
Roberto Lazzarini
MGMonserrat Gerardo-Ramírez
Monserrat Gerardo-Ramírez
AEAlejandro Escobedo-Calvario
Alejandro Escobedo-Calvario
LCLisette Chavez-Rodríguez
Lisette Chavez-Rodríguez
LBLeticia Bucio-Ortiz
Leticia Bucio-Ortiz
Aim: Cholestasis remains a partially characterized disease. Evidence has been gained that it is a systemic disease that begins in the liver but significantly impacts other organs and systems such as the kidney, heart, and intestine, among others. One of the primary damage mechanisms is the generation of reactive oxygen species (ROS), which eventually leads to oxidative stress, impacting canalicular morphology and actin cytoskeleton changes that could worsen the problem. These characteristics are also observed in the kidney and intestine. The work focused on addressing the intestine effects of intrahepatic cholestasis induced by α-naphthyl isothiocyanate (ANIT) and the protective response of the hepatocyte growth factor (HGF). Methods: The 10- to 12-week-old CD1 male mice were treated with ANIT and then treated or not with HGF; intestine damage was addressed by histology, immunohistochemistry (IHC) of specific markers, oxidative stress, and apoptosis. Results: Results show changes in the intestine histology, particularly the colon and ileum, induced by the cholestasis. HGF treatment restored the histology presentation and reverted the oxidative damage, clearly indicating a healing response. This observation was supported by an increment in anti-inflammatory macrophages (CD163+) in the HGF treatment. Conclusions: The data prove that HGF induces a protective and repairing response in the intestine under cholestatic challenges.